Correction: Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Authors: Ruanne V. Barnabas, MBChB, MSc, DPhil, Elizabeth R. Brown, ScD, Anna Bershteyn, PhD, Helen C. Stankiewicz Karita, MD, Christine Johnston, MD, MPH
Journal: Annals of Internal Medicine (2021)

CorrectionsMarch 2021Correction: Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 InfectionFREEThis correction concerns the following article:Original ResearchMar 2021Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 InfectionFREERuanne V. Barnabas, MBChB, MSc, DPhil, Elizabeth R. Brown, ScD, Anna Bershteyn, PhD, Helen C. Stankiewicz Karita, MD, Christine Johnston, MD, MPHRuanne V. Barnabas, MBChB, MSc, DPhilUniversity of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington (R.V.B., E.R.B., C.J., A.L.G., K.R.J., A.W.), Elizabeth R. Brown, ScDUniversity of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington (R.V.B., E.R.B., C.J., A.L.G., K.R.J., A.W.), Anna Bershteyn, PhDNew York University Grossman School of Medicine, New York, New York (A.B., L.E.T., A.K.), Helen C. Stankiewicz Karita, MDUniversity of Washington, Seattle, Washington (H.C.S., T.T.S., M.L.K., K.K.T., S.M., H.S.H., L.K., M.W., C.C., H.Y.C., J.M.B.), Christine Johnston, MD, MPHUniversity of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington (R.V.B., E.R.B., C.J., A.L.G., K.R.J., A.W.)https://doi.org/10.7326/L21-0009 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In the article by Barnabas and colleagues (1), corrections were made to Table 2 for a secondary analysis result. Updates also were made to the Results section of the article regarding the subset. The online article was corrected on 18 December 2020.Reference1. Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection. A randomized trial. Ann Intern Med. 2020. doi:10.7326/M20-6519 LinkGoogle Scholar Comments 0 Comments Sign In to Submit A Comment PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection Ruanne V. Barnabas , Elizabeth R. Brown , Anna Bershteyn , Helen C. Stankiewicz Karita , Christine Johnston , Lorna E. Thorpe , Angelica Kottkamp , Kathleen M. Neuzil , Miriam K. Laufer , Meagan Deming , Michael K. Paasche-Orlow , Patricia J. Kissinger , Alfred Luk , Kristopher Paolino , Raphael J. Landovitz , Risa Hoffman , Torin T. Schaafsma , Meighan L. Krows , Katherine K. Thomas , Susan Morrison , Harald S. Haugen , Lara Kidoguchi , Mark Wener , Alexander L. Greninger , Meei-Li Huang , Keith R. Jerome , Anna Wald , Connie Celum , Helen Y. Chu , and Jared M. Baeten , Hydroxychloroquine COVID-19 PEP Study Team* Metrics Cited byDry powder formulation of azithromycin for COVID-19 therapeuticsUse of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis March 2021Volume 174, Issue 3 Page: 435 ePublished: 16 March 2021 Issue Published: March 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...